New drug combination delayed disease progression for subgroup of women with metastatic breast cancer

(American Association for Cancer Research) Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news